Evandro de Azambuja
埃万德罗·德·阿赞布贾
MD, PhD
Head of Research研究主任
👥Biography 个人简介
Evandro de Azambuja at Institut Jules Bordet is a leading European breast cancer trialist and one of the principal investigators of the APHINITY trial demonstrating pertuzumab adjuvant benefit. He leads the Breast International Group (BIG) statistical center.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
APHINITY Trial
Was among the principal investigators of APHINITY, demonstrating that adjuvant pertuzumab plus trastuzumab reduces invasive disease events in HER2+ early breast cancer.
BIG Statistical Leadership
Leads statistical operations and data management for Breast International Group cooperative trials, enabling global HER2+ breast cancer research.
Representative Works 代表性著作
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
NEJM (2017)
APHINITY trial.
Pertuzumab, Trastuzumab, and Standard Adjuvant Chemotherapy for Women with Early, HER2-Positive Breast Cancer: Updated results of APHINITY
Journal of Clinical Oncology (2021)
6-year APHINITY follow-up.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 埃万德罗·德·阿赞布贾 的研究动态
Follow Evandro de Azambuja's research updates
留下邮箱，当我们发布与 Evandro de Azambuja（Institut Jules Bordet, Universite Libre de Bruxelles）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment